ArticleJournal of translational medicine2025
Urinary metabolome at birth in patients with hypoxic-ischemic encephalopathy treated with therapeutic hypothermia and long-term neurodevelopmental outcomes: a 7-year follow up.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Whole-Blood Gene Expression and Hypoxic-Ischemic Encephalopathy at Birth.JAMA network open · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypoxic-ischemic encephalopathy (HIE) is a leading cause of neonatal mortality and morbidity, yet no validated biomarkers currently exist to predict long-term outcomes. We investigated the potential of the neonatal urinary metabolomic profile as a predictor of long-term neurodevelopmental outcomes in HIE newborns treated with therapeutic hypothermia (TH).
methodsWe conducted a longitudinal study in neonates with HIE undergoing TH. Urine samples collected during TH were analyzed using untargeted metabolomics via mass spectrometry. Based on long-term follow-up outcomes, patients were categorized into two groups: the adverse outcome (AO) group, defined by perinatal death, cerebral palsy, and/or an intelligence quotient (IQ) < 70, and the favourable outcome (FO) group, defined as absence of CP and IQ ≥ 70. Additionally, we assessed the predictive value of early neonatal brain magnetic resonance imaging (MRI) in relation to the aforementioned outcomes.
resultsAmong 53 newborns treated with TH for HIE, long-term follow-up outcomes were available for 40; 29 were classified as FO and 11 as AO group. To mitigate bias, 11 FO patients were matched with 11 AO patients based on similar perinatal characteristics. Metabolomic analysis identified 21 metabolites distinguishing the two groups, with γ-butyrolactone, N-acetyl-galactosamine/glucosamine, Aldosterone, and Creatinine showing independent discriminative capability among groups. Brain MRI demonstrated a 67% positive and 96% negative predictive value for adverse outcomes.
conclusionsThe identified metabolites are implicated in neuromodulation and neuronal susceptibility to damage, suggesting their potential as prognostic markers for long-term outcomes in HIE and warranting further investigation. This is the first study linking the acute-phase metabolomic profile with long-term neurodevelopmental outcomes in HIE neonates, supporting its prognostic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.